KYOTO -- Takara Bio will ramp up its domestic capacity to produce reagents for PCR tests to 8 million specimens a month, eight times more than the current level, as early as this summer.
The move comes as the company aims to build a stable supply of reagents for PCR tests without relying on supplies from Western reagent makers. The government will support the plan through subsidies.
